Acura Pharmaceuticals Price to Free Cash Flow Ratio 2012-2021 | ACUR
Historical price to free cash flow ratio values for Acura Pharmaceuticals (ACUR) since 2012.
| Acura Pharmaceuticals Price to Free Cash Flow Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM FCF per Share | Price to FCF Ratio |
| 2026-06-17 | 0.00 | 0.00 | |
| 2021-12-31 | 0.50 | $-0.01 | 0.00 |
| 2021-09-30 | 0.53 | $-0.01 | 0.00 |
| 2021-06-30 | 0.66 | $-0.03 | 0.00 |
| 2021-03-31 | 0.33 | $-0.04 | 0.00 |
| 2020-12-31 | 0.21 | $-0.02 | 0.00 |
| 2020-09-30 | 0.25 | $-0.01 | 0.00 |
| 2020-06-30 | 0.35 | $0.05 | 6.53 |
| 2020-03-31 | 0.28 | $0.01 | 0.00 |
| 2019-12-31 | 0.23 | $-0.02 | 0.00 |
| 2019-09-30 | 0.30 | $-0.09 | 0.00 |
| 2019-06-30 | 0.14 | $-0.17 | 0.00 |
| 2019-03-31 | 0.18 | $-0.16 | 0.00 |
| 2018-12-31 | 0.11 | $-0.18 | 0.00 |
| 2018-09-30 | 0.19 | $-0.24 | 0.00 |
| 2018-06-30 | 0.36 | $-0.31 | 0.00 |
| 2018-03-31 | 0.51 | $-0.44 | 0.00 |
| 2017-12-31 | 0.40 | $-0.28 | 0.00 |
| 2017-09-30 | 0.45 | $-0.02 | 0.00 |
| 2017-06-30 | 0.56 | $-0.06 | 0.00 |
| 2017-03-31 | 0.60 | $-0.19 | 0.00 |
| 2016-12-31 | 0.77 | $-0.48 | 0.00 |
| 2016-09-30 | 1.60 | $-0.74 | 0.00 |
| 2016-06-30 | 1.85 | $-0.75 | 0.00 |
| 2016-03-31 | 2.83 | $-0.74 | 0.00 |
| 2015-12-31 | 2.50 | $-0.36 | 0.00 |
| 2015-09-30 | 2.35 | $-0.49 | 0.00 |
| 2015-06-30 | 4.94 | $-0.59 | 0.00 |
| 2015-03-31 | 3.95 | $-0.62 | 0.00 |
| 2014-12-31 | 2.25 | $-1.14 | 0.00 |
| 2014-09-30 | 3.92 | $-1.22 | 0.00 |
| 2014-06-30 | 5.45 | $-1.27 | 0.00 |
| 2014-03-31 | 7.30 | $-1.39 | 0.00 |
| 2013-12-31 | 8.35 | $-1.43 | 0.00 |
| 2013-09-30 | 9.50 | $-1.31 | 0.00 |
| 2013-06-30 | 9.40 | $-1.17 | 0.00 |
| 2013-03-31 | 10.65 | $-0.96 | 0.00 |
| 2012-12-31 | 11.10 | $-0.76 | 0.00 |
| 2012-09-30 | 8.70 | $-0.78 | 0.00 |
| 2012-06-30 | 15.70 | $-0.77 | 0.00 |
| 2012-03-31 | 17.30 | $1.28 | 13.49 |
| 2011-12-31 | 17.45 | $1.27 | 13.75 |
| 2011-09-30 | 17.00 | $1.29 | 13.21 |
| 2011-06-30 | 19.35 | $1.35 | 14.30 |
| 2011-03-31 | 15.80 | $-0.56 | 0.00 |
| 2010-12-31 | 16.55 | $-0.69 | 0.00 |
| 2010-09-30 | 12.45 | $-0.79 | 0.00 |
| 2010-06-30 | 12.55 | $-0.93 | 0.00 |
| 2010-03-31 | 26.95 | $-1.06 | 0.00 |
| 2009-12-31 | 26.65 | $-0.59 | 0.00 |
| 2009-09-30 | 25.55 | $-0.34 | 0.00 |
| 2009-06-30 | 29.90 | $-0.27 | 0.00 |
| 2009-03-31 | 32.10 | $0.72 | 44.57 |
| 2008-12-31 | 36.70 | $0.41 | 89.60 |
| 2008-09-30 | 35.15 | $3.54 | 9.94 |
| 2008-06-30 | 39.75 | $3.40 | 11.68 |
| 2008-03-31 | 43.70 | $2.46 | 17.79 |
| 2007-12-31 | 30.50 | $2.45 | 12.45 |
| 2007-09-30 | 84.00 | $-0.88 | 0.00 |
| 2007-06-30 | 55.25 | $-0.75 | 0.00 |
| 2007-03-31 | 42.50 | $-0.77 | 0.00 |
| 2006-12-31 | 37.00 | $-0.79 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Halsey Drug Company, Inc. is engaged in the manufacture, sale and distribution of generic drugs. A generic drug is the chemical and therapeutic equivalent of a brand-name drug for which patent protection has expired. The company sells its generic drug products under its Halsey label and under private-label arrangements with drugstore chains and drug wholesalers. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |